Loading…
← CockpitCompetitor Analysis › SKAN.SW SKAN Group AGOpen in the cockpit ↗

SKAN Group AGSKAN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Specialties

Swiss maker of isolators and barrier/containment systems used in sterile pharmaceutical manufacturing.

≈ A niche Swiss equivalent of Syntegon for isolatorsMomentum leader 82
Mkt cap
$1.85B
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$2.73M
20-day average traded
Fwd P/E
49.5×
forward earnings
ROIC−WACC
+12.5 pp
WACC 5.0%
Hurdle
+2 pp
Req g minus delivered
Next earnings
125 days
23 Mar 2027
Close · CHFCHF 69.30
1D+0.1%
1W-0.3%
1M-4.8%
3M+6.1%
6M+40.3%
YTD+31.2%
1Y+44.8%
ATR %2.7%
52w lowhigh10.5% off high

What SKAN does

Swiss maker of isolators and barrier/containment systems used in sterile pharmaceutical manufacturing.

Earns mainly from project orders for custom isolators (sealed chambers that keep sterile drug filling free of contamination), with delivery spread over months, and adds recurring revenue from qualification, spare parts and service on installed units. Order intake follows pharma and biotech capacity building.

In one line: A niche Swiss equivalent of Syntegon for isolators.

Products and services

  • Isolators for sterile fill-finish
  • Containment systems
  • Qualification & spare-parts services

Customers

  • Pharma & biotech manufacturers
  • CDMOs

Where it sits in the supply chain

  • Pharma manufacturing equipment
  • Aseptic processing
  • Isolators & cleanroom containment

What could go right

  • Biologics/sterile injectable manufacturing growth
  • CDMO capacity expansion

What could go wrong

  • Lumpy large-project order timing
  • Customer concentration

Moat: narrow (customer qualification, process know-how, regulatory licence). Validated equipment inside regulated sterile lines is costly to requalify.

Headquarters: Allschwil, Switzerland · Employees: 1,755

Named competitors

  • Syntegon Technology private or unlisted
  • Bausch+Strobel private or unlisted
  • Optima Pharma private or unlisted
  • Getinge GETI-B.ST

SKAN at a glance

Size SKAN (SKAN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $1.85B, the 96th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 69.30 on 18 Nov 2026.

Performance Over six months the shares gained 40.3%, against +1.5% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 9.4% over the last twelve months (peer median +14.5%); the operating margin is 10.7% (peer median 14.6%).

Valuation It trades at 49.5× forward earnings against a peer median of 23.8× (4th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 12.5 points above its cost of capital (5.0% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026SKAN.SW 130Peer median 99
Six months, rebased to 100: SKAN against the median of its 20 peers (local-currency closes).

SKAN financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 363MCHF 333MCHF 361MCHF 320MCHF 277M
Revenue growth—-8%+13%+16%—
Gross profitCHF 265MCHF 243MCHF 253MCHF 228MCHF 190M
EBITDACHF 52.9MCHF 38.6MCHF 57.0MCHF 50.1MCHF 40.2M
Net incomeCHF 30.0MCHF 16.3MCHF 38.8MCHF 26.3MCHF 19.0M
Free cash flowCHF 21.5MCHF 21.0M-CHF 4.33M-CHF 24.9MCHF 35.4M
Capital expenditureCHF 38.1MCHF 45.9MCHF 53.8MCHF 35.3MCHF 28.9M
Total debtn/aCHF 131MCHF 10.6MCHF 6.49MCHF 23.6M

Quarterly statements and history in the cockpit →

SKAN competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%268AMED69601066POLYMED7716CHEMMLMAT301363EMBLAKMTSINSP8086BONEXVCYTBFLYESTASKAN.SW6-month return →1-month return →
Up and to the right = strong over both horizons. SKAN is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%20×40×60×268AMED69601066POLYMED7716CHEMM301363EMBLAXRAYINSPBONEXVCYT6699SKAN.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SKAN is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%268A696010667716CHEMMLMAT301363EMBLAXRAYINSPBONEXVCYT6699SKAN.SWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. SKAN is the large dot.

SKAN competitors and peer comparison

Head to head with its named competitors (SKAN.SW vs GETI-B.ST)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
SKAN SKAN.SW$1.85B+40%+9%11%49.5×13.8%
Getinge GETI-B.ST$7.45B+40%-4%14%21.1×5.0%

How SKAN compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SKAN against its 20 peers (data as of 18 Nov 2026)
MeasureSKAN.SWPeer medianRank in peer set
1-month return-4.8%-2.0%10th lowest of 21
6-month return+40.3%+1.5%3rd highest of 20
Distance from 52-week high-10.5%-25.5%4th highest of 21
Revenue growth (TTM)+9.4%+14.5%9th lowest of 21
Operating margin10.7%14.6%9th lowest of 21
Forward P/E49.5×23.8×4th most expensive of 17
Growth the price implies (Req g, 7 yrs)13.8%12.6%7th most demanding of 14
Growth delivered (Del g)+11.7%+14.0%5th lowest of 14
Hurdle (Req g minus delivered)+2.1 pp-10.3 pp5th most demanding of 14
ROIC minus cost of capital+12.5 pp-0.6 pp5th highest of 21
EV / EBITDA30.4×15.7×6th most expensive of 16
Net debt / EBITDA0.8×-1.0×6th most indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Establishment Labs ESTAUnited States$2.11B+1%+38%-7%n/an/an/a

Questions

Who are SKAN's main competitors?
Named competitors: Syntegon Technology (private or unlisted), Bausch+Strobel (private or unlisted), Optima Pharma (private or unlisted), Getinge (GETI-B.ST). The cockpit's measured peer set (industry) also includes Molbio Diagnostics (MOLBIO.NS), Rigaku (268A.T), Medartis (MED.SW), Fukuda Denshi (6960.T), Shandong Weigao Group Medical Polymer (1066.HK), Poly Medicure (POLYMED.NS).
Is SKAN expensive compared with its peers?
On forward p/e it trades at 49.5× against a peer median of 23.8×, 4th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has SKAN stock performed?
Over six months to 18 Nov 2026 the shares returned +40.3% against +1.5% for the median peer; over one year +44.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.